Amylin (14-20) (human)
Need Assistance?
  • US & Canada:
    +
  • UK: +

Amylin (14-20) (human)

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

The formation of amyloid deposits by IAPP can play a central role in the pathogenesis of type 2 diabetes. In addition to the amyloidogenic 20-29 region, the NFLVHSS domain (IAPP 14-20) tends to aggregate and seems to be involved in plaque formation.

Category
Functional Peptides
Catalog number
BAT-014737
CAS number
121341-77-3
Molecular Formula
C36H54N10O11
Molecular Weight
802.89
IUPAC Name
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2,4-diamino-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoic acid
Synonyms
H-Asn-Phe-Leu-Val-His-Ser-Ser-OH; L-asparagyl-L-phenylalanyl-L-leucyl-L-valyl-L-histidyl-L-seryl-L-serine; (2S,5S,8S,11S,14S,17S,20S)-8-((1H-imidazol-4-yl)methyl)-20,22-diamino-17-benzyl-2,5-bis(hydroxymethyl)-14-isobutyl-11-isopropyl-4,7,10,13,16,19,22-heptaoxo-3,6,9,12,15,18-hexaazadocosan-1-oic acid
Appearance
White Powder
Purity
≥95%
Density
1.337±0.06 g/cm3 (Predicted)
Boiling Point
1373.3±65.0°C (Predicted)
Sequence
NFLVHSS
Storage
Store at -20°C
Solubility
Soluble in DMSO, Water
InChI
InChI=1S/C36H54N10O11/c1-18(2)10-23(42-31(51)24(11-20-8-6-5-7-9-20)41-30(50)22(37)13-28(38)49)33(53)46-29(19(3)4)35(55)43-25(12-21-14-39-17-40-21)32(52)44-26(15-47)34(54)45-27(16-48)36(56)57/h5-9,14,17-19,22-27,29,47-48H,10-13,15-16,37H2,1-4H3,(H2,38,49)(H,39,40)(H,41,50)(H,42,51)(H,43,55)(H,44,52)(H,45,54)(H,46,53)(H,56,57)/t22-,23-,24-,25-,26-,27-,29-/m0/s1
InChI Key
NYWRQILLKJSDDP-UIRCOLITSA-N
Canonical SMILES
CC(C)CC(C(=O)NC(C(C)C)C(=O)NC(CC1=CN=CN1)C(=O)NC(CO)C(=O)NC(CO)C(=O)O)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(=O)N)N
1. Destabilization of human IAPP amyloid fibrils by proline mutations outside of the putative amyloidogenic domain: is there a critical amyloidogenic domain in human IAPP?
Andisheh Abedini, Daniel P Raleigh J Mol Biol. 2006 Jan 13;355(2):274-81. doi: 10.1016/j.jmb.2005.10.052. Epub 2005 Nov 8.
Islet amyloid polypeptide (IAPP; amylin) is responsible for amyloid formation in type-2 diabetes. Not all organisms form islet amyloid, and amyloid formation correlates strongly with variations in primary sequence. Studies of human and rodent IAPP have pointed to the amino acid residues 20-29 region as the important amyloid-modulating sequence. The rat 20-29 sequence contains three proline residues and does not form amyloid, while the human sequence contains no proline and readily forms amyloid. This has led to the view that the 20-29 region constitutes a critical amyloidogenic domain that dictates the properties of the entire sequence. The different behavior of human and rat IAPP could be due to differences in the 20-29 region or due simply to the fact that multiple proline residues destabilize amyloid fibrils. We tested how critical the 20-29 region is by studying a variant identical with the human peptide in this segment but with three proline residues outside this region. We designed a variant of the amyloidogenic 8-37 region of human IAPP (hIAPP(8-37) 3xP) with proline substitutions at positions 17, 19 and 30. Compared to the wild-type, the 3xP variant was much easier to synthesize and had dramatically greater solubility. Fourier transform infra red spectroscopy, transmission electron microscopy, Congo red staining and thioflavin-T binding indicate that this variant has a reduced tendency to form beta-sheet structure and forms deposits with much less structural order than the wild-type. Far-UV CD studies show that the small amount of beta-sheet structure developed by hIAPP(8-37) 3xP after long periods of incubation dissociates readily into random-coil structure upon dilution into Tris buffer. The observation that proline substitutions outside the putative core domain effectively abolish amyloid formation indicates that models of IAPP aggregation must consider contributions from other regions.
2. Ferret islet amyloid polypeptide (IAPP): characterization of in vitro and in vivo amyloidogenicity
Johan F Paulsson, Marie-Odile Benoit-Biancamano, Lauge Schäffer, Kirsten Dahl Amyloid. 2011 Dec;18(4):222-8. doi: 10.3109/13506129.2011.627956. Epub 2011 Nov 2.
Diabetes in the domestic ferret (Mustela putorius furo) has previously been described and the purpose of this study was to evaluate if the ferret could serve as a model for the study of β-cell degeneration associated with formation of islet amyloid. The nucleotide and amino acid sequence of ferret islet amyloid polypeptide (IAPP) 1-37 was identified and the synthesized peptide was studied with regards to in vitro amyloidogenicity and potential cellular toxicity in a comparative approach to human, cat and the nonamyloidogenic rat IAPP. Ferret IAPP forms amyloid-like fibrils, but with a longer lag phase than human and cat IAPP and the aggregation process was shown to reduce cell viability of cultured β-cells, but with less potency than these two amyloidogenic counterparts. Immunohistochemistry of ferret pancreas confirmed IAPP expression in the islets of Langerhans, but no islet amyloid was found in a very limited sample size of one diabetic and five healthy ferrets. Islet amyloid has never been described in ferrets, and it is not possible to determine if it is due to lack of studies/material or to the fact that the ferret's life span is too short to present with such pathology.
3. Identification of a novel human islet amyloid polypeptide beta-sheet domain and factors influencing fibrillogenesis
E T Jaikaran, C E Higham, L C Serpell, J Zurdo, M Gross, A Clark, P E Fraser J Mol Biol. 2001 May 4;308(3):515-25. doi: 10.1006/jmbi.2001.4593.
Human islet amyloid polypeptide (hIAPP) accumulates as pancreatic amyloid in type 2 diabetes and readily forms fibrils in vitro. Investigations into the mechanism of hIAPP fibril formation have focused largely on residues 20 to 29, which are considered to comprise a primary amyloidogenic domain. In rodents, proline substitutions within this region and the subsequent beta-sheet disruption, prevents fibril formation. An additional amyloidogenic fragment within the C-terminal sequence, residues 30 to 37, has been identified recently. We have extended these observations by examining a series of overlapping peptide fragments from the human and rodent sequences. Using protein spectroscopy (CD/FTIR), electron microscopy and X-ray diffraction, a previously unrecognised amyloidogenic domain was localised within residues 8 to 20. Synthetic peptides corresponding to this region exhibited a transition from random coil to beta-sheet conformation and assembled into fibrils having a typical amyloid-like morphology. The comparable rat 8-20 sequence, which contains a single His18Arg substitution, was also capable of assembling into amyloid-like fibrils. Examination of peptide fragments corresponding to residues 1 to 13 revealed that the immediate N-terminal region is likely to have only a modulating influence on fibril formation or conformational conversion. The contributions of charged residues as they relate to the amyloid-forming 8-20 sequence were also investigated using IAPP fragments and by assessing the effects of pH and counterions. The identification of these principal amyloidogenic sequences and the effects of associated factors provide details on the IAPP aggregation pathway and structure of the peptide in its fibrillar state.
Online Inquiry
Verification code
Inquiry Basket